医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mitsui Chemicals Acquired US Corning SunSensors® Photochromic Lens Material

2014年05月20日 PM10:00
このエントリーをはてなブックマークに追加


 

TOKYO

Mitsui Chemicals, Inc. (TOKYO:4183 ; President & CEO: Tsutomu Tannowa) announced the acquisition of Corning Incorporated’s (NYSE:GLW) SunSensors® operations on May 15, 2014. Through the acquisition, Mitsui Chemicals moves to bolster its world-class ophthalmic lens material business while breaking into the rapidly growing global photochromic lens market. The company will aggressively develop and sell competitive new photochromic lens materials.

Mitsui Chemicals offers high to low refractive index ophthalmic lens material and coatings to meet the diverse needs of people around the world. The company is known as a premier provider of ophthalmic lens materials with its thin and light “MRTM Series” super durable and clear high refractive index lens material, which allows progressive design. The world-leading “MRTM Series” revolutionized ophthalmic lens material standards and is now regarded as the global standard for lens quality around the world.

Similarly, Corning has been a driving force behind the photochromic lens market since the 1960s, when it first launched its photochromic eyeglass lens materials. The company has continued to lead the market with innovations, including its SunSensors® brand of photochromic organic lens materials.

Mitsui Chemicals’ acquisition of Corning’s photochromic lens material business, which is showing staggering growth in not only developed markets but also in developing markets such as India and Brazil, will contribute to the growth of the company’s vision care materials business while expanding the product lineup to improve its ophthalmic lens material solutions and contribute to optimized customer service.

Mitsui Chemicals will use its efficient global customer and sales network to bolster sales growth of SunSensors® products while intensifying development of new competitive vision care materials including next-generation photochromic lens material to strengthen the company’s position as a provider of new value for its customers.

Outline

1. Subject of acquisition: Business rights of photochromic lens material, patents for photochromic monomer, and trademark rights of SunSensors® and SunSensors®+

2. Effect of acquisition:

a. New business: Entry into significantly growing photochromic lens materials market and strengthening of ophthalmic lens material business  (current estimated world photochromic lens market 150 billion yen)

b. New product development: Synergy of Mitsui Chemicals’ superior ophthalmic lens material technology with Corning’s superior photochromic technology to bolster development of next-generation photochromic lens material

c. Product portfolio to meet diverse market needs: Optimal customer service through addition of photochromic lens material to lineup which includes high to low refractive index ophthalmic lens material to meet diverse global market needs

d. Use of sales network: Expansion of SunSensors® market through use of Mitsui Chemicals’ global customer and sales network

e. Use of manufacturing technology: Use of Group’s superior lens material synthesis and manufacturing technology to establish a more efficient production system for photochromic lens material

About Mitsui Chemicals

Mitsui Chemicals (Tokyo:4183, ISIN:JP3888300005) contributes broadly to society by providing high-quality products and services to customers through innovations and creation of materials and products while keeping in harmony with the global environment. Mitsui Chemicals’ business portfolio includes automotive materials, healthcare, food packaging, energy, agrochemicals, and others.

The Mitsui Chemicals Group traces its origins back to 1912. The Group now has over 135 companies and around 14,500 employees in 27 countries worldwide. In the fiscal year ending March 2013, the Group posted consolidated sales of US$ 14,952 million.

More information can be found at http://www.mitsuichem.com/index.htm

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140519005079/en/

CONTACT

Mitsui Chemicals
Corporate Communications Division
Yuri
Matsunaga, +81-3-6253-2100
Yuuri.Matsunaga@mitsui-chem.co.jp

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表